Growth hormone and Prader-Willi syndrome

Aaron L. Carrel, Phillip D.K. Lee, Harriette R. Mogul

Research output: Chapter in Book/Report/Conference proceedingChapter

19 Scopus citations

Abstract

In the previous edition of this textbook, various lines of evidence for the occurrence of a defi ciency in the growth hormone (GH) axis were reviewed as one of several sections in a chapter entitled "Endocrine and Metabolic Aspects of Prader-Willi Syndrome."76 At that time, it was suggested that GH therapy may have benefi cial effects on growth and body composition in individuals with PWS. Over the succeeding decade, a number of scientifi c investigations have provided defi nitive evidence in support of these suggestions.16,37,72,73 In 2000, biosynthetic GH became the fi rst and, to date, only medication to receive regulatory approval for treatment of children with PWS. In addition, it appears that GH may also have potential utility in adults with PWS.61,86 This chapter presents a comprehensive review of relevant physiology and pathophysiology of the GH system and GH treatment effi cacy and safety in PWS.

Original languageEnglish (US)
Title of host publicationManagement of Prader-Willi Syndrome
Subtitle of host publicationThird Edition
PublisherSpringer New York
Pages201-241
Number of pages41
ISBN (Print)0387253971, 9780387253978
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Growth hormone and Prader-Willi syndrome'. Together they form a unique fingerprint.

  • Cite this

    Carrel, A. L., Lee, P. D. K., & Mogul, H. R. (2006). Growth hormone and Prader-Willi syndrome. In Management of Prader-Willi Syndrome: Third Edition (pp. 201-241). Springer New York. https://doi.org/10.1007/978-0-387-33536-0_7